Here's Why The Cooper Companies (COO) is a Strong Growth Stock

Company Overview - The Cooper Companies is a global medical device company with two main segments: CooperVision (CVI) and CooperSurgical (CSI) [11] - CVI focuses on contact lenses, particularly in daily silicone hydrogel lenses, torics, multifocals, and myopia management, with flagship products like MyDay and MiSight [11] - CSI provides products and services in fertility and women's health, including in-vitro fertilization (IVF) solutions and contraceptives [11] Investment Ratings - COO is rated 2 (Buy) on the Zacks Rank, indicating a positive outlook for the stock [12] - The company has a VGM Score of B, suggesting a favorable combination of value, growth, and momentum characteristics [12] Growth Potential - COO has a Growth Style Score of B, forecasting year-over-year earnings growth of 9.5% for the current fiscal year [12] - An analyst has revised their earnings estimate upwards for fiscal 2026, with the Zacks Consensus Estimate increasing to $4.51 per share [12] - The company has an average earnings surprise of +4.1%, indicating strong performance relative to expectations [12] Investment Recommendation - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, COO is recommended for investors' consideration [13]